Stock Price Quote

NECTAR LIFESCIENCES LTD.

NSE : NECLIFEBSE : 532649ISIN CODE : INE023H01027Industry : Pharmaceuticals & DrugsHouse : Private
BSE24.09-0.23 (-0.95 %)
PREV CLOSE ( ) 24.32
OPEN PRICE ( ) 24.27
BID PRICE (QTY) 24.01 (1563)
OFFER PRICE (QTY) 24.15 (1647)
VOLUME 7461
TODAY'S LOW / HIGH ( )24.09 24.27
52 WK LOW / HIGH ( )20.05 56.39
NSE24.08-0.27 (-1.11 %)
PREV CLOSE( ) 24.35
OPEN PRICE ( ) 24.35
BID PRICE (QTY) 24.08 (1000)
OFFER PRICE (QTY) 24.14 (113)
VOLUME 25408
TODAY'S LOW / HIGH( ) 24.06 24.35
52 WK LOW / HIGH ( )20.02 56.5
1D 1M 3M 1Y 3Y 5Y

STOCK SUMMARY

Incorporation Year : 27-06 1995
Management Info
Sanjiv Goyal - Chairman Sanjiv Goyal - Managing Director
Registered Office

Address Village Saidpura,Tehsil Dera Bassi,District Sahibzada Ajit Singh Nagar,
Mohali Dist,
Punjab-140507

Phone 01762-534001 / 534002

Email sales@neclife.com

Website www.neclife.com

Registrars Details
K FIN Technologies Ltd.-(Karvy Fintech Pvt Ltd.)
Karvy Selenium Tower B, Plot 31-32,Gachibowli,Financial District,Nanakramguda,Hyderabad
Listing : BSE, NSE, Luxembourg

NEWS

05Apr Nectar Lifesciences informs about cert
Pursuant to Regulation 74(5) of Securities and Exchange Board of India (..
04Apr Nectar Lifescience informs about discl
With reference to point no. 2 of Annexure 1 of letter no. NLL/CS/2024-43..
11Mar Nectar Lifesciences receives 7 observa
European Directorate for the Quality of Medicines & HealthCare (EDQM..
11Mar Nectar Lifesciences hits lower circuit
Nectar Lifesciences is locked at its lower circuit limit of Rs. 26.38, d..
28Feb Nectar Lifesciences informs about resi
Pursuant to Regulation 30 of the Securities and Exchange of Board of Ind..

Financials

in Millions
QTR Dec 24 ANNUAL 24
Net Profit78.399999999999950.0100000000023
Gross Profit 125.47 182.750000000002
Operating Profit 452.831661.35
Net Sales 4549.8216856.32

ROLLING FORWARD P/E (EOD)

EVENT CALENDAR

peer group

RPG Life Sciences (BSE)
peergroup  2221.95 (2.47%)
M.Cap ( in Cr)3586.40
Pfizer (BSE)
peergroup  5019.95 (0.82%)
M.Cap ( in Cr)22779.40
Dishman Carbogen Amc (BSE)
peergroup  245.00 (11.36%)
M.Cap ( in Cr)3449.23
Jubilant Pharmova (BSE)
peergroup  1014.15 (2.15%)
M.Cap ( in Cr)15813.43
Neuland Laboratories (BSE)
peergroup  11206.15 (0.17%)
M.Cap ( in Cr)14352.60

Shareholding Pattern

NON-INSTITUTION 53.67%
PROMOTERS 44.53%
GOVERNMENT 0.02%
MUTUAL FUNDS/UTI 0%
FI/BANKS/INSURANCE 0%
FII 0%

About Nectar Lifesciences Ltd.

Nectar Lifesciences Ltd. was incorporated in the year 1995. Its today's share price is 24.09. Its current market capitalisation stands at Rs 545.4 Cr. In the latest quarter, company has reported Gross Sales of Rs. 19258.32 Cr and Total Income of Rs.17084.12 Cr. The company's management includes Sanjaymohan Singh Rawat, Puneet Sud, Indu Pal Kaur, Kuldip Kumar Bhasin, Rupinder Tewari, Meena Verma, Sanjiv Goyal, Sanjiv Goyal.

It is listed on the BSE with a BSE Code of 532649 , NSE with an NSE Symbol of NECLIFE and ISIN of INE023H01027. It's Registered office is at Village Saidpura,Tehsil Dera Bassi,District Sahibzada Ajit Singh NagarMohali Dist-140507, Punjab. Their Registrars are K FIN Technologies Ltd.-(Karvy Fintech Pvt Ltd.) It's auditors are Ashwani K Gupta & Associates, Datta Singla & Co, Deepak Jindal & Co

© NIRMAL BANG. All rights reserved

Designed , Developed & Content Powered by Accord Fintech Pvt. Ltd.

Open an Account
FOR AFREE *DEMAT & BROKING ACCOUNT

Please fill in the details below

Close X

(Note - You will receive a call from our sales executive)

CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.